Ovarian cancer (OC; International Classification of Diseases, Revision 10 [ICD-10] code: C56) and cancer of the fallopian tubes and other uterine adnexa (ICD-10: C57) are leading causes of cancer mortality in women. Cancer of the ovary, fallopian tubes, and other uterine adnexa are collectively referred to as OC throughout this report. In the US, the American Cancer Society reports that OC accounts for more deaths than any other cancer of the female reproductive system.
GlobalData epidemiologists forecast the diagnosed incident cases of OC in the 7MM, to increase from 68,804 cases in 2015 to 77,457 cases in 2025, at an Annual Growth Rate (AGR) of 1.26%. The US will have the highest number of diagnosed incident cases of OC in the 7MM throughout the forecast period. The five year diagnosed prevalent cases of OC are also expected to increase from 191,345 cases in 2015 to 218,905 cases in 2025, at an AGR of 1.44%. Additionally, in 2015, there were 191,345 five-year diagnosed prevalent cases of OC in the 7MM, which is expected to increase to 218,905 cases by 2025, at an AGR of 1.44%. Among the 7MM, the US had the highest number of five-year diagnosed prevalent cases of OC in 2015 and 2025, at 73,597 cases and 89,778 cases, respectively.
GlobalData's epidemiological forecast for the diagnosed incident and five-year diagnosed prevalent cases of OC in the 7MM is supported by age- and sex-specific incidence data drawn from national cancer registries. The one- to five-year relative survival data, which were used for the five-year diagnosed prevalent cases forecast, are supported by country-specific population-based studies that are representative of the national population in the respective markets. The use of a consistent methodology across the 7MM to forecast the diagnosed incident cases and the five-year diagnosed prevalent cases of OC allows for a meaningful comparison of the forecast diagnosed incident cases and the forecast five-year diagnosed prevalent cases of OC in these markets.
The Ovarian Cancer EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and global trends for OC in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases of OC segmented by sex, age (beginning at 18 years and ending at =85 years). Additionally, it includes a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of OC and in these markets.
The OC epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Table of Contents
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global Trends
2.3.1 7MM Incidence Trends
2.3.2 7MM Trends in Relative Survival
2.4 Forecast Methodology
2.4.1 Sources Used Tables
2.4.2 Forecast Assumptions and Methods
2.4.3 Sources Not Used
2.5 Epidemiological Forecast for Ovarian Cancer (2015–2025)
2.5.1 Diagnosed Incident Cases of Ovarian Cancer
2.5.2 Age-Specific Diagnosed Incident Cases of Ovarian Cancer
2.5.3 Age-Standardized Diagnosed Incidence of Ovarian Cancer
2.5.4 Diagnosed Incident Cases of Primary Peritoneal Cancer
2.5.5 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer and Primary Periotneal Cancer
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of the Analysis
2.6.3 Strengths of the Analysis
3.2 About the Authors
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.3 About GlobalData
3.4 About EpiCast
List of Tables
Table 1: Risk Factors of OC
Table 2: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of OC and PPC
Table 3: 7MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of OC and PPC
Table 4: 7MM, Diagnosed Incident Cases of OC, Ages ≥18 Years, N, 2015–2025
Table 5: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015
Table 6: 7MM, Diagnosed Incident Cases of PPC, Ages ≥18 Years, N, 2015–2025
Table 7: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ≥18 Years, N, 2015–2025
List of Figures
Figure 1: 7MM, Diagnosed Incidence Rate of OC, Cases per 100,000, All Ages, Women, 1998─2007
Figure 2: 7MM, Diagnosed Incident Cases of OC, Ages ≥18 Years, N, 2015–2025
Figure 3: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of OC, Ages≥18 Years, Cases per 100,000, 2015
Figure 5: 7MM, Diagnosed Incident Cases of PPC, Ages ≥18 Years, N, 2015–2025
Figure 6: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ≥18 Years, N, 2015–2025
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Personal and transaction information are kept safe from unauthorised use.
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.